An Integrated Approach to Uncover Driver Genes in Breast Cancer Methylation Genomes

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Shen, Xiaopei ^a   Li, Shan ^a   Zhang, Lin ^a   Li, Hongdong ^a   Hong, Guini ^a   Zhou, XianXiao ^a   Zheng, Tingting ^a   Zhang, Wenjing ^a   Hao, Chunxiang ^a   Shi, Tongwei ^a   Liu, Chunyang ^b   Guo, Zheng ^a,b  

^a UNIVERSITY OF ELECTRONIC SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; HISTONE DEACETYLASE 1; SURVIVIN; TRANSCRIPTION FACTOR E2F2; TRANSCRIPTION FACTOR E2F3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CPG ISLAND; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; METHYLATION; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; TUMOR GENE;

BREAST NEOPLASMS; CLUSTER ANALYSIS; CPG ISLANDS; DATABASES, GENETIC; DNA METHYLATION; EPIGENESIS, GENETIC; EPIGENOMICS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; REPRODUCIBILITY OF RESULTS;

EID: 84875994819     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061214     Document Type: Article

References (54)

1. Esteller M, Sparks A, Toyota M, Sanchez-Cespedes M, Capella G, et al. (2000) Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res 60: 4366-4371.
2. Yamamoto H, Oue N, Sato A, Hasegawa Y, Yamamoto H, et al. (2010) Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase. Oncogene 29: 2036-2046.
3. Shen X, He Z, Li H, Yao C, Zhang Y, et al. (2012) Distinct functional patterns of gene promoter hypomethylation and hypermethylation in cancer genomes. PLoS One 7: e44822.
4. Ushijima T, Asada K, (2010) Aberrant DNA methylation in contrast with mutations. Cancer Sci 101: 300-305.
5. De Carvalho DD, Sharma S, You JS, Su SF, Taberlay PC, et al. (2012) DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell 21: 655-667.
6. Kalari S, Pfeifer GP, (2010) Identification of driver and passenger DNA methylation in cancer by epigenomic analysis. Adv Genet 70: 277-308.
7. Pulukuri SM, Estes N, Patel J, Rao JS, (2007) Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer. Cancer Res 67: 930-939.
8. Wang Z, Zhang J, Zhang Y, Lim SH, (2006) SPAN-Xb expression in myeloma cells is dependent on promoter hypomethylation and can be upregulated pharmacologically. Int J Cancer 118: 1436-1444.
9. Son KS, Kang HS, Kim SJ, Jung SY, Min SY, et al. (2010) Hypomethylation of the interleukin-10 gene in breast cancer tissues. Breast 19: 484-488.
10. Ambatipudi S, Gerstung M, Pandey M, Samant T, Patil A, et al. (2012) Genome-wide expression and copy number analysis identifies driver genes in gingivobuccal cancers. Genes Chromosomes Cancer 51: 161-173.
11. Akavia UD, Litvin O, Kim J, Sanchez-Garcia F, Kotliar D, et al. (2010) An integrated approach to uncover drivers of cancer. Cell 143: 1005-1017.
12. Kim YA, Wuchty S, Przytycka TM, (2011) Identifying causal genes and dysregulated pathways in complex diseases. PLoS Comput Biol 7: e1001095.
13. Efroni S, Schaefer CF, Buetow KH, (2007) Identification of key processes underlying cancer phenotypes using biologic pathway analysis. PLoS One 2: e425.
14. Edgar R, Domrachev M, Lash AE, (2002) Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207-210.
15. Bibikova M, Lin Z, Zhou L, Chudin E, Garcia EW, et al. (2006) High-throughput DNA methylation profiling using universal bead arrays. Genome Res 16: 383-393.
16. Irizarry RA, Warren D, Spencer F, Kim IF, Biswal S, et al. (2005) Multiple-laboratory comparison of microarray platforms. Nat Methods 2: 345-350.
17. Benjamini Y, Hochberg Y, (1995) Controlling the false discovery rate: apractical and powerful approach to multiple testing. Journal of the royal statistical society Series B (Methodological) 57: 289-300.
18. Dedeurwaerder S, Desmedt C, Calonne E, Singhal SK, Haibe-Kains B, et al. (2011) DNA methylation profiling reveals a predominant immune component in breast cancers. EMBO Mol Med 3: 726-741.
19. Gong X, Wu R, Zhang Y, Zhao W, Cheng L, et al. (2010) Extracting consistent knowledge from highly inconsistent cancer gene data sources. BMC Bioinformatics 11: 76.
20. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, et al. (2004) A census of human cancer genes. Nat Rev Cancer 4: 177-183.
21. Yang Y, Fu LM, (2003) TSGDB: a database system for tumor suppressor genes. Bioinformatics 19: 2311-2312.
22. Zanzoni A, Montecchi-Palazzi L, Quondam M, Ausiello G, Helmer-Citterich M, et al. (2002) MINT: a Molecular INTeraction database. FEBS Lett 513: 135-140.
23. Bader GD, Betel D, Hogue CW, (2003) BIND: the Biomolecular Interaction Network Database. Nucleic Acids Res 31: 248-250.
24. Hermjakob H, Montecchi-Palazzi L, Lewington C, Mudali S, Kerrien S, et al. (2004) IntAct: an open source molecular interaction database. Nucleic Acids Res 32: D452-455.
25. Peri S, Navarro JD, Kristiansen TZ, Amanchy R, Surendranath V, et al. (2004) Human protein reference database as a discovery resource for proteomics. Nucleic Acids Res 32: D497-501.
26. Mewes HW, Dietmann S, Frishman D, Gregory R, Mannhaupt G, et al. (2008) MIPS: analysis and annotation of genome information in 2007. Nucleic Acids Res 36: D196-201.
27. Salwinski L, Miller CS, Smith AJ, Pettit FK, Bowie JU, et al. (2004) The Database of Interacting Proteins: 2004 update. Nucleic Acids Res 32: D449-451.
28. Kanehisa M, Goto S, (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28: 27-30.
29. Joshi-Tope G, Gillespie M, Vastrik I, D'Eustachio P, Schmidt E, et al. (2005) Reactome: a knowledgebase of biological pathways. Nucleic Acids Res 33: D428-432.
30. Lage K, Karlberg EO, Storling ZM, Olason PI, Pedersen AG, et al. (2007) A human phenome-interactome network of protein complexes implicated in genetic disorders. Nat Biotechnol 25: 309-316.
31. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
32. Vogelstein B, Kinzler KW, (2004) Cancer genes and the pathways they control. Nat Med 10: 789-799.
33. Bunney TD, Katan M, (2010) Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer 10: 342-352.
34. Zhang M, Yao C, Guo Z, Zou J, Zhang L, et al. (2008) Apparently low reproducibility of true differential expression discoveries in microarray studies. Bioinformatics 24: 2057-2063.
35. Zou J, Hao C, Hong G, Zheng J, He L, et al. (2012) Revealing weak differential gene expressions and their reproducible functions associated with breast cancer metastasis. Comput Biol Chem 39: 1-5.
36. Potter C, Harris AL, (2004) Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 3: 164-167.
37. Yu JS, Koujak S, Nagase S, Li CM, Su T, et al. (2008) PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. Oncogene 27: 4657-4665.
38. Frau M, Tomasi ML, Simile MM, Demartis MI, Salis F, et al. (2012) Role of transcriptional and posttranscriptional regulation of methionine adenosyltransferases in liver cancer progression. Hepatology 56: 165-175.
39. Zhang Y, Song M, Cui ZS, Li CY, Xue XX, et al. (2011) Down-regulation of TSG101 by small interfering RNA inhibits the proliferation of breast cancer cells through the MAPK/ERK signal pathway. Histol Histopathol 26: 87-94.
40. Fan H, Villegas C, Huang A, Wright JA, (1998) The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. Cancer Res 58: 1650-1653.
41. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
42. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100: 8418-8423.
43. Ben-Dor A, Shamir R, Yakhini Z, (1999) Clustering gene expression patterns. J Comput Biol 6: 281-297.
44. Kawai H, Li H, Avraham S, Jiang S, Avraham HK, (2003) Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. Int J Cancer 107: 353-358.
45. Witt O, Deubzer HE, Milde T, Oehme I, (2009) HDAC family: What are the cancer relevant targets? Cancer Lett 277: 8-21.
46. Vince JE, Pantaki D, Feltham R, Mace PD, Cordier SM, et al. (2009) TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (tnf) to efficiently activate nf-{kappa}b and to prevent tnf-induced apoptosis. J Biol Chem 284: 35906-35915.
47. Bertucci F, Birnbaum D, (2008) Reasons for breast cancer heterogeneity. J Biol 7: 6.
48. Finetti P, Cervera N, Charafe-Jauffret E, Chabannon C, Charpin C, et al. (2008) Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. Cancer Res 68: 767-776.
49. Issa JP, (2007) DNA methylation as a therapeutic target in cancer. Clin Cancer Res 13: 1634-1637.
50. Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, et al. (2012) Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene.
51. Ehrlich M, (2009) DNA hypomethylation in cancer cells. Epigenomics 1: 239-259.
52. Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, et al. (2012) Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res 14: R79.
53. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, et al. (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070.
54. Sawan C, Herceg Z, (2010) Histone modifications and cancer. Adv Genet 70: 57-85.